06.03.2017 • NewsDede WillamsKeytrudacancer

UK Rejects Keytruda as First Lung Cancer Option

(c) Merck & Co
(c) Merck & Co

Britain's health agency National Institute for Health and Care Excellence (NICE), which has responsibility for assessing the cost-effectiveness of medical treatments, has decided not to recommend that the National Health Service (NHS) allow the use of Merck & Co's immunotherapy drug Keytruda in patients in England and Wales with newly diagnosed with non-small cell lung cancer patients.

The NHS in Scotland and Ireland is run by authorities in the two devolved countries.

NICE initially rejected use of the US drugmaker’s chemotherapy medicine for patients who did not respond to prior treatment, but greenlighted this application in December 2016 after

Merck (which trades as MSD outside the US and Canada) agreed to further cuts in the drug’s price.

Keytruda is already approved in the UK as a cost-effective treatment for melanoma. However, according to NICE's draft guidance, which will be subject to public consultation until Mar. 21, data from clinical trials in the initial lung cancer application has not been reliable enough.

“The exact size of the overall survival gain for Keytruda compared to the current standard of care was uncertain because of the immaturity of the data," an agency spokesperson told UK media.

Even with a discount, the high cost of the drug, which has a list price of around £2,360 per 100 mg vial, means that the Quality Adjusted Life Year (QALY) was likely to cost in excess of £50,000 –  well above NICE’s  usual threshold for cost-effectiveness – reports said.

The US drugmaker said it was disappointed by the NICE decision, adding that its new UK managing director will work with British authorities with to find a way to resolve the problems.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.